Cite
HARVARD Citation
Chevallier, P. et al. (n.d.). BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle. European journal of haematology. pp. 552-556. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Chevallier, P. et al. (n.d.). BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle. European journal of haematology. pp. 552-556. [Online].